Back to Journals » Drug Design, Development and Therapy » Volume 9

Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson’s disease: a pharmacoinformatics study

Authors Mirza MU, Mirza AH, Ghori N, Ferdous S

Received 17 August 2014

Accepted for publication 23 September 2014

Published 18 December 2014 Volume 2015:9 Pages 187—198

DOI https://doi.org/10.2147/DDDT.S72794

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Shu-Feng Zhou

Muhammad Usman Mirza,1 A Hammad Mirza,2 Noor-Ul-Huda Ghori,3 Saba Ferdous4

1Centre for Research in Molecular Medicine, The University of Lahore, Lahore, Pakistan; 2Department of Bioscience, COMSATS Institute of Information Technology, Sahiwal, Pakistan; 3Atta-ur-Rehman School of Applied Biosciences, National University of Science and Technology, Islamabad, Pakistan; 4Institute of Structural and Molecular Biology, University College London, UK

Abstract: Parkinson’s disease (PD) is caused by loss in nigrostriatal dopaminergic neurons and is ranked as the second most common neurodegenerative disorder. Dopamine receptor D3 is considered as a potential target in drug development against PD because of its lesser side effects and higher degree of neuro-protection. One of the prominent therapies currently available for PD is the use of dopamine agonists which mimic the natural action of dopamine in the brain and stimulate dopamine receptors directly. Unfortunately, use of these pharmacological therapies such as bromocriptine, apomorphine, and ropinirole provides only temporary relief of the disease symptoms and is frequently linked with insomnia, anxiety, depression, and agitation. Thus, there is a need for an alternative treatment that not only hinders neurodegeneration, but also has few or no side effects. Since the past decade, much attention has been given to exploitation of phytochemicals and their use in alternative medicine research. This is because plants are a cheap, indispensable, and never ending resource of active compounds that are beneficial against various diseases. In the current study, 40 active phytochemicals against PD were selected through literature survey. These ligands were docked with dopamine receptor D3 using AutoDock and AutoDockVina. Binding energies were compared to docking results of drugs approved by the US Food and Drug Administration against PD. The compounds were further analyzed for their absorption, distribution, metabolism, and excretion-toxicity profile. From the study it is concluded that glycyrrhetinic acid and E.resveratroloside are potent compounds having high binding energies which should be considered as potential lead compounds for drug development against PD.

Keywords: AutoDock, AutoDockVina, molecular docking, parkinson’s disease, glycyrrhetinic acid, E.resveratroloside

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Readers of this article also read:

Relationship between variations in posterior vitreous detachment and visual prognosis in idiopathic epiretinal membranes

Ota A, Tanaka Y, Toyoda F, Shimmura M, Kinoshita N, Takano H, Kakehashi A

Clinical Ophthalmology 2016, 10:7-11

Published Date: 21 December 2015

Neurological soft signs might be endophenotype candidates for patients with deficit syndrome schizophrenia

Albayarak Y, Akyol ES, Beyazyüz M, Baykal S, Kuloglu M

Neuropsychiatric Disease and Treatment 2015, 11:2825-2831

Published Date: 29 October 2015

Stroke and diabetic ketoacidosis – some diagnostic and therapeutic considerations

Jovanovic A, Stolic RV, Rasic DV, Markovic-Jovanovic SR, Peric VM

Vascular Health and Risk Management 2014, 10:201-204

Published Date: 8 April 2014

Bone repair by periodontal ligament stem cell-seeded nanohydroxyapatite-chitosan scaffold

Ge S, Zhao N, Wang L, Yu M, Liu H, Song A, Huang J, Wang G, Yang P

International Journal of Nanomedicine 2012, 7:5405-5414

Published Date: 10 October 2012

New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo

Zhou T, Jia X, Li H, Wang J, Zhang H, A Y, Zhang ZZ

International Journal of Nanomedicine 2011, 6:1527-1534

Published Date: 22 July 2011

Poly (ε-caprolactone) nanofibrous ring surrounding a polyvinyl alcohol hydrogel for the development of a biocompatible two-part artificial cornea

Bakhshandeh H, Soleimani M, Shah Hosseini S, Hashemi H, Shabani I, Shafiee A, Behesht Nejad AH, Erfan M, Dinarvand R, Atyabi F

International Journal of Nanomedicine 2011, 6:1509-1515

Published Date: 14 July 2011

Epigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidine

Steven E McCormack, Erica D Warlick

OncoTargets and Therapy 2010, 3:157-165

Published Date: 22 July 2010